3. Baseline IgE levels.
| Study | IgE level (mean) |
| Bardelas 2012 | 180 IU/mL ± 130.5 |
| Boulet 1997 | 1152.4 IU/mL (data skewed: SD 2304.5) |
| Busse 2001 | 179.26 IU/mL |
| Busse 2011 | Unclear |
| Chanez 2010 | 220.2 IU/mL ± 151.96 |
| Djukanovic 2004 | Median: omalizumab group: 155.5; placebo group: 141 |
| Fahy 1997 | 141.5 IU/mL |
| Fahy 1999 | 230.1 IU/mL |
| Garcia 2012 | Not stated |
| Gevaert 2012 | Not stated |
| Hanania 2011 | 176.9 IU/mL |
| Holgate 2004 | 266.26 IU/mL |
| INNOVATE | Between 30 and 1300 IU/mL (no mean given) |
| Lanier 2009 | 469.7 IU/mL ± 338.0 |
| Massanari 2010 | 176.63 IU/mL ± 138.018 |
| Milgrom 1999 | 441.7 IU/mL |
| Milgrom 2001 | 339.85 IU/mL |
| NCT00096954 | ≥ 30 to ≤ 1300 IU/mL; no mean given |
| NCT01007149 | Unclear |
| Ohta 2009 | 508.1 IU/mL |
| Prieto 2006 | 199.2 IU/mL |
| SOLAR | 193.6 IU/mL |
| Solèr 2001 | 214.38 IU/mL |
| van Rensen 2009 | Unclear |